P
Pharus Diagnostics
PharusDx specializes in early cancer detection using advanced RNA-based technology
About Pharus Diagnostics
PharusDx operates in the healthcare sector, focusing on early cancer detection through advanced RNA-based technology. The company serves healthcare providers and patients by offering a precise and affordable screening solution that integrates diverse omics data for comprehensive pancancer detection. Utilizing a single blood draw, PharusDx's proprietary technology and database map out real-time health status, making early cancer detection possible and potentially curable. The business model revolves around providing a simple testing process that seamlessly fits into existing health checkup protocols, ensuring accessibility and ease for all users. Revenue is generated through partnerships with healthcare institutions and direct service offerings to patients. By combining machine learning with novel biomarker combinations, PharusDx aims to transform cancer management and prevention, ultimately extending the time patients can spend with their loved ones.
Source: Dealroom company dataAt a glance
- Founded
- 2022
- Headquarters
- Zhubei City, Taiwan
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
CK Hutchison
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pharus Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pharus Diagnostics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.